A
A
A

Regeneron宣布Cemdisiran(Livsayis)获FDA批准用于治疗全身型重症肌无力(gMG)

·7 hours ago发布
  • Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals

  • Livsayis isRegeneron's first approved siRNA therapy and neurology medicine

 

TARRYTOWN, N.Y.,Nov. 18, 2026(GLOBE NEWSWIRE) --Regeneron Pharmaceuticals, Inc.(NASDAQ: REGN) today announced that theU.S. Food and Drug Administration(FDA) has approved Livsayis™ (cemdisiran) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive, the predominant form of the disease. Livsayis is a novel, complement component factor 5 (C5)-directed small interfering RNA (siRNA) therapeutic that reduces levels of circulating C5 protein, limiting terminal complement activation, a key driver of the disease. It is the first and only approved siRNA therapy in gMG and the onlyFDA-approved gMG treatment administered subcutaneously four times a year.

 

“For people living with gMG, every day can be unpredictable, due to fluctuating muscle weakness and fatigue. They may also experience severe exacerbations that can be life-threatening. Many still experience suboptimal disease control, whether from waning of therapeutic effect, inadequate response or high treatment burden,” saidTuan Vu, M.D., Professor of Neurology at theUniversity of South Florida Morsani College of Medicine, Division Director forNeuromuscular Medicine and EMG Laboratories, and a global principal investigator of the NIMBLE trial. “In the Phase 3 NIMBLE trial, Livsayis delivered rapid, deep disease control – maintained through the end of dosing intervals – and offers a four-times-a-year subcutaneous dosing schedule. These results highlight how a first-of-its-kind approach can address a key driver of disease and provide a compelling treatment option.”

 

TheFDAapproval was based on results from the Phase 3 NIMBLE trial. Livsayis demonstrated the following least square mean change from baseline:

  • 4.5-point improvement on the Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score at 24 weeks (0.4 standard error [SE]) compared to a 2.2-point improvement with placebo (0.5 SE). This corresponded to a placebo-adjusted improvement of 2.3 points (p=0.0005). MG-ADL is a clinician-administered patient-reported assessment of daily functions impacted by gMG, such as talking, chewing, swallowing, breathing, vision and mobility. The proportion of MG-ADL responders with at least 3-point improvement at week 24 was greater for Livsayis (76.6%) compared to placebo (44.1%, p<0.001).

  • 4.2-point improvement in Quantitative Myasthenia Gravis (QMG) total score at 24 weeks (0.6 SE) compared to a 1.5-point improvement with placebo (0.7 SE), corresponding to a placebo-adjusted improvement of 2.8 points (p=0.0015). QMG is a clinician-administered assessment of muscle function, including vision, speaking/swallowing, breathing and limb mobility. The proportion of QMG responders with at least a 5-point improvement at week 24 was greater for Livsayis (48.4%) compared to placebo (19.0%, p<0.001).

  • Rapid onset of clinically meaningful benefit in MG-ADL (2.5 points), with improvements seen as early as two weeks of starting treatment that deepened over time.

  • Sustained disease control and symptom relief through 24 weeks, with MG-ADL scores maintained and no indication of waning efficacy.

 

The prescribing information for Livsayis includes a Boxed Warning for serious meningococcal infections in addition to warnings and precautions for other serious infections, consistent with otherFDA-approved medicines that reduce C5 activity. The most common adverse reactions (≥5%) in patients treated with Livsayis and more frequently than placebo were injection site reactions, viral infections and urinary tract infections. Livsayis is available only through a restricted program called the Livsayis Risk Evaluation and Mitigation Strategy (REMS), which is also consistent with otherFDA-approved medicines that reduce C5 activity. Details of the Important Safety Information are included below.

 

“Livsayis is Regeneron’s first approved medicine in neurology, and an important new option for people living with generalized myasthenia gravis who need effective disease control without a heavy treatment burden,” saidGeorge D. Yancopoulos, M.D., Ph.D., Board Co-Chair, President and Chief Scientific Officer ofRegeneron. “As Regeneron’s first approved siRNA therapy, this approval marks a meaningful step forward for our neuroscience pipeline as we relentlessly pursue bold, new approaches to transform care for people living with serious neurological diseases.”

 

“Individuals living with gMG experience profound muscle weakness that can affect how they talk, see, breathe and move, and with it their ability to carry out everyday activities,” saidSamantha Masterson, President & CEO,Myasthenia Gravis Foundation of America. “This approval is a positive milestone for the gMG community, reflecting continued progress on outcomes that matter most to patients. With Livsayis, those living with generalized myasthenia gravis have a new option that may help maintain disease control while reducing the burden treatment can place on daily life.”

 

Regeneronis committed to supporting people living with rare diseases and ensuring patients who have been prescribed Livsayis access to their medication. Regeneron’s myRARE™ program offers resources to help patients and healthcare providers, including product information, insurance benefit verification, and information about potential financial support. To learn about myRARE, visit myRARE.com or call 1-833-4my-RARE (1-833-469-7273).

 

A regulatory submission for Livsayis for the treatment of gMG is currently under review in the European Union, with a decision anticipated in the second half of 2027. Regulatory submissions are planned in additional markets, includingJapan.

 

About gMG


gMG is a rare, chronic autoimmune disease characterized by unpredictable, debilitating and potentially life-threatening muscle weakness. In the most common form of the disease, abnormal anti-AChR antibodies activate the complement system including C5, disrupting communication between nerves and muscles, which contributes to damage at the neuromuscular junction. For these patients, the disease affects muscles throughout the body, resulting in extreme fatigue and difficulties with facial expression, speech, swallowing, mobility, breathing as well as severe exacerbations, including myasthenic crisis that can impair breathing to the point of requiring hospitalization. Worldwide, an estimated 150 to 200 out of every million people have MG. In theU.S., the disease impacts approximately 85,000 people.

 

About Livsayis


Livsayis is the first approved siRNA therapy for gMG and the only gMG treatmentFDA-approved to be administered subcutaneously four times per year (every three months).

 

Livsayis is a complement C5-directed siRNA that degrades the messenger RNA (mRNA) that encodes the C5 protein, thereby blocking C5 production, reducing circulating levels of C5 and inhibiting terminal complement activation, a key driver of AChR-positive gMG.

 

Regeneronis solely responsible for the development, manufacturing, and commercialization of Livsayis through a worldwide licensing agreement with Alnylam.

 

About the NIMBLE trial


NIMBLE is the largest global, interventional gMG trial conducted to date. In this ongoing Phase 3, randomized, double-blind, placebo-controlled trial, Livsayis is being evaluated in patients with anti-AChR antibody-positive gMG who can continue background immunosuppressants based on the investigator’s discretion. Participants were randomized to receive one of four subcutaneous regimens: Livsayis every three months; a combination of Livsayis and a C5-inhibiting monoclonal antibody every 4 weeks; C5-inhibiting monoclonal antibody every 4 weeks; or placebo every 4 weeks.

 

The primary endpoint assessed changes in the MG-ADL total score from baseline to week 24. The MG-ADL scale is an eight-question clinician-administered, patient-reported tool that measures how gMG affects aspects of daily life and provides a total score ranging from 0 to 24. The key secondary endpoint was the change from baseline in QMG total score at week 24. The QMG is a clinician-administered 13-item standardized assessment evaluating muscle function that provides a total score ranging from 0 to 39. In both MG-ADL and QMG, a higher total score indicates greater disease severity, and a larger reduction in total score indicates greater improvement in disease symptoms and better treatment effect.

 

About Regeneron


Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

 

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

文章关键词: RegeneronCemdisiran(Livsayis)FDA全身型重症肌无力(gMG)
下载PDF
0
发布文章
0
关注人数